Search filters
Filters
Clear All

Phase

  • 13
  • 1
  • 10
  • 6
  • 175
  • 206
  • 166
  • 1
  • 5
  • 200

Found 206 cc-cancer-center trials

A listing of cc-cancer-center medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

UPCC 11924: An Open-Label, Phase 1/2 Study of ORIC-114 as a Single Agent or in Combination with Chemotherapy, in Patients with Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

99 years and younger
All genders
The purpose of this study is to establish the recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of ORIC-114 as a Single Agent or in Combination with Chemotherapy when administered to patients with advanced solid tumors harboring an EGFR or …
Learn More

UPCC 04522: Substudy 2: A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents in Combination with Pembrolizumab in Treatment Naïve Patients with PD-L1 Positive Advanced Non-small Cell Lung Cancer (NSCLC)

99 years and younger
All genders
This is a substudy of an umbrella study (MK-3475-U1). Subjects will be enrolled to the screening protocol and then subsequently enrolled to one of the substudies. This substudy examines MK-4830 in combination with pembrolizumab in participants with PD-L1 positive NSCLC.
Learn More

UPCC 09924 An Open-label, Phase 1/2 Dose-Escalation, Dose Expansion and Cohort Expansion Study Evaluating the Safety, PK and Clinical Activity of FMC-376 in Participants with KRAS G12C Mutated Locally Advanced Unresectable or Metastatic Solid Tumors

99 years and younger
All genders
Please refer to Protocol Section 3.1 (Study Objectives). Please refer to Protocol 3.2 (Study Endpoints). Please refer to Protocol 3.2 (Study Endpoints).
Learn More

UPCC 13924: A Multicenter, Open-Label Phase 1/1B Dose-Finding, Safety, and Pharmacokinetic Study of MBRC-101, an Anti-EPHA5 Monomethyl Auristatin E (MMAE) Antibody Drug Conjugate, in Advanced Refractory Solid Tumors

99 years and younger
All genders
This is a first-in-human (FIH), open label Phase 1/1b study in patients with advanced metastatic solid tumors refractory to standard treatment. Phase 1 will identify potential optimal biologically relevant doses (OBRD) and the maximum tolerated dose (MTD) of MBRC-101 at one 1 or more dosing regimens. Phase 1b will evaluate …
Learn More

UPCC 16524: A Multicenter, Randomized, Phase 3 Study to Assess the Efficacy and Safety of Intratumorally Administered INT230-6 (SHAO, vinblastine, cisplatin) Compared With US Standard of Care in Adult Participants With Locally Recurrent, Inoperable, or

99 years and younger
All genders
To compare Overall Survival (OS) for INT230-6 vs United States (US) Standard of Care (SOC) in participants with unresectable or metastatic liposarcoma, undifferentiated pleomorphic sarcoma or leiomyosarcoma who have disease progression prior to study enrollment following no more than 2 standard therapies, which must have included an anthracycline-based regimen, unless …
Learn More

UPCC 02522 A Phase III, double-blind, placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (

99 years and younger
All genders
This is a Phase III, randomised, double-blind, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) in combination with oleclumab (MEDI9447) or durvalumab (MEDI4736) with monalizumab (IPH2201) in adults with locally advanced (Stage III), unresectable NSCLC, who have not progressed following platinum-based cCRT.
Learn More

UPCC 18524: A Phase 2 Trial of Ixazomib for Kaposi Sarcoma

99 years and younger
All genders
This phase II trial studies how well ixazomib works in treating patients with Kaposi sarcoma. Ixazomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. We would like to rely on CIRB as the IRB of record for this study.
Learn More

UPCC 36424 Phase 2, Open-Label, Multicenter, Dose-Optimization Study of the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Profiles of Volasertib in Combination With Decitabine in Patients With Relapsed/Refractory Acute Myeloid Leukemia

99 years and younger
All genders
The purpose of this study is to test the safety and tolerability of volasertib combined with decitabine in participants with relapsed/refractory acute myeloid leukemia. We would like to rely on Advarra IRB as the IRB of record for this study.
Learn More

UPCC 39424 An Observational Long-term Follow-up Study of Patients Who Received Prior Caribou Cell Therapy

99 years and younger
All genders
This is a non-interventional, long-term safety study of allogeneic CAR-T cell therapy in patients who have participated in a prior Caribou-sponsored clinical study, in a special access program, or in another study such as an IIT. Its purpose of is to collect long-term observational data to identify and understand potential …
Learn More

UPCC 44424: A Phase 1 Study of KTX-1001, an Oral, First-In-Class, Selective, and Potent MMSET Catalytic Inhibitor that Suppresses H3K36me2 in Patients with Relapsed and Refractory Multiple Myeloma

99 years and younger
All genders
The purpose of this study is to test the safety and tolerability of KTX-1001 in patients with Relapsed and Refractory Multiple Myeloma. We would like to rely on Advarra as the IRB of record.
Learn More
181 - 190 of 206